Halozyme Therapeutics Files 8-K
Ticker: HALO · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
Related Tickers: HALO
TL;DR
Halozyme filed an 8-K on 10/14/25, mostly procedural stuff, no big news yet.
AI Summary
On October 14, 2025, Halozyme Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate reporting, but the lack of specific details in the excerpt means its immediate impact on investors is unclear.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, with no immediate indication of significant risk or material events.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- October 14, 2025 (date) — Date of Report
- 12390 El Camino Real (location) — Principal Executive Offices Address
- San Diego, CA 92130 (location) — Principal Executive Offices City, State, Zip
FAQ
What is the primary purpose of this 8-K filing by Halozyme Therapeutics?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was this 8-K report filed?
The report was filed on October 14, 2025.
What is Halozyme Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 12390 El Camino Real, San Diego, CA 92130.
What is the Commission File Number for Halozyme Therapeutics?
The Commission File Number is 001-32335.
What is the SIC code for Halozyme Therapeutics?
The Standard Industrial Classification (SIC) code is 2836 for Biological Products (No Diagnostic Substances).
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-10-14 06:45:15
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
Filing Documents
- halo-20251014.htm (8-K) — 32KB
- halozymestatementoncmsfi.htm (EX-99.1) — 18KB
- halo-20251014_g1.jpg (GRAPHIC) — 15KB
- halozymestatementoncmsfi001.jpg (GRAPHIC) — 69KB
- halozymestatementoncmsfi002.jpg (GRAPHIC) — 197KB
- halozymestatementoncmsfi003.jpg (GRAPHIC) — 70KB
- halozymestatementoncmsfi004.jpg (GRAPHIC) — 74KB
- halozymestatementoncmsfi005.jpg (GRAPHIC) — 215KB
- halozymestatementoncmsfi006.jpg (GRAPHIC) — 181KB
- halozymestatementoncmsfi007.jpg (GRAPHIC) — 119KB
- halozymestatementoncmsfi008.jpg (GRAPHIC) — 136KB
- halozymestatementoncmsfi009.jpg (GRAPHIC) — 103KB
- halozymestatementoncmsfi010.jpg (GRAPHIC) — 130KB
- halozymestatementoncmsfi011.jpg (GRAPHIC) — 156KB
- halozymestatementoncmsfi012.jpg (GRAPHIC) — 92KB
- 0001159036-25-000039.txt ( ) — 2326KB
- halo-20251014.xsd (EX-101.SCH) — 2KB
- halo-20251014_lab.xml (EX-101.LAB) — 21KB
- halo-20251014_pre.xml (EX-101.PRE) — 12KB
- halo-20251014_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 14, 2025, Halozyme Therapeutics, Inc., a Delaware corporation (the "Company"), issued a statement (the "Statement") on recently issued final IPAY 2028 guidance for Medicare price negotiations issued by the U.S. Centers for Medicare & Medicaid Services. The Statement includes the Company's long-term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE partner product subcutaneous sales. A copy of the Statement can be found on the Company's corporate website and is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information set forth under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc. (Registrant) Dated: October 14, 2025 By: /s/ Mark Snyder Mark Snyder Senior Vice President, General Counsel and Corporate Secretary